Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEACE 4 trial of acetylsalicylic acid and atorvastatin in castration-resistant prostate cancer
2023-508072-11-00Phase 3Authorised
- Sponsor
- Gustave Roussy
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of ruxolitinib cream and atorvastatin in castration-resistant prostate cancer (CRPC) (2 arms), sponsored by Gustave Roussy. Primary endpoint: Overall survival. Planned start Nov 2023; status: authorised.
02
Drugs
ruxolitinib creamatorvastatin
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2023-508072-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508072-11-00.